Golgi Neurosciences and Breye Therapeutics announce successful closing of P2X7 receptor antagonist program transfer

  • Collaboration to advance development of innovative oral small molecule therapeutics for retinal disorders

Milan, Italy and Copenhagen, Denmark, 25 July 2023 – Golgi Neurosciences S.r.l., the biotech incubator dedicated to the development of new treatments for devastating diseases, and Breye Therapeutics ApS, a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases, today announces a collaboration to develop the P2X7 receptor antagonist programme.

Read more…